Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4LM9F | — |
didn't get the antigen of Arexvy, that is that only the diluent portion was injected to the patient./ administered the Adjuvant portion of AREXVY only; didn't get the antigen of Arexvy, that is that only the diluent portion was injected to the patient./ administered the Adjuvant portion of AREXVY only; This non-serious case was reported by a physician via call center representative and described the occurrence of inappropriate preparation of medication in a 89-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 4LM9F, expiry date 10-OCT-2026) for prophylaxis. On 17-JUL-2025, the patient received Arexvy. On 17-JUL-2025, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: didn't get the antigen of Arexvy, that is that only the diluent portion was injected to the patient./ administered the Adjuvant portion of AREXVY only) and inappropriate dose of vaccine administered (Verbatim: didn't get the antigen of Arexvy, that is that only the diluent portion was injected to the patient./ administered the Adjuvant portion of AREXVY only). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 18-JUL-2025 The patient was administered the Adjuvant portion of Arexvy only, which led to Inappropriate preparation of medication and inappropriate dose of vaccine administered. The lot number provided was from the adjuvant. The reporter did not have the lot from the antigen.